Overview
- 16 inspections across 15 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2024-04-30.
At a glance
Inspections
16
Sites
15
Observations
0
Career since
May 2017
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| AUTOLUS LIMITED | 30 Apr 2024 | Biologics | On file |
| Novartis Pharma Stein AG | 20 Nov 2023 | Biologics | |
| GenIbet Biopharmaceuticals | 31 Jan 2023 | Biologics | On file |
| Seres Therapeutics Inc | 14 Dec 2022 | Biologics | |
| Aimmune Therapeutics Manufacturing, LLC | 9 Dec 2022 | Biologics |
Sites inspected
AUTOLUS LIMITEDStevenage, United Kingdom1 insp.
Novartis Pharma Stein AGStein Ag, Switzerland1 insp.
GenIbet BiopharmaceuticalsOeiras, Portugal1 insp.
Seres Therapeutics IncCambridge, United States1 insp.
Aimmune Therapeutics Manufacturing, LLCWaltham, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Miriam M Ngundi3 shared
Jessica Chery2 shared
Kula N Jha2 shared
Lori P Peters2 shared
Andrew E Timmons1 shared
Unnee Ranjan1 shared
Ekaterina Allen1 shared
Anissa M Cheung1 shared
Debra M Emerson1 shared
Arulvathani P Arudchandran1 shared
Full investigator report
Get the verbatim findings behind Kathleen R Jones' inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site